Jazz Pharmaceuticals PLC

Latest Results (22.12.2024):

Revenue Growth

In the third quarter of 2024, Jazz Pharmaceuticals PLC reported total revenues of $1.05 billion, marking a 9% increase compared to the same period in 2023. This growth was driven by strong performance in both the neuroscience and oncology segments, with notable contributions from products like Xywav and Epidiolex/Epidyolex.

Neuroscience Segment

The neuroscience segment, including high-sodium oxybate AG royalty revenue, generated $760.9 million in the third quarter of 2024, reflecting an 8% increase from $704.0 million in the third quarter of 2023. This growth was primarily attributed to increased sales of Xywav and Epidiolex/Epidyolex, as well as higher royalty revenues from high-sodium oxybate AG.

Oncology Performance

Jazz Pharmaceuticals PLC's oncology net product sales reached $284.8 million in the third quarter of 2024, a 9% increase compared to the same period in 2023. This was supported by higher sales of Defitelio/defibrotide, which rose by 38% to $65.8 million, and Zepzelca, which increased by 10% to $85.8 million.

Earnings Per Share

For the third quarter of 2024, Jazz Pharmaceuticals PLC reported a GAAP net income of $215.1 million, or $3.42 per diluted share, compared to $146.8 million, or $2.14 per diluted share, in the third quarter of 2023. The non-GAAP adjusted net income was $416.9 million, or $6.61 per diluted share, up from $340.1 million, or $4.84 per diluted share, in the same period of the previous year.

Financial Outlook

Jazz Pharmaceuticals PLC reaffirmed its total revenue guidance for 2024, projecting revenues between $4.0 billion and $4.1 billion. The company also adjusted its guidance for neuroscience and oncology revenues, while raising its GAAP and non-GAAP EPS guidance ranges, reflecting confidence in its strategic pipeline and ongoing product performance.